Feasibility and usability of a regional hub model for colorectal cancer services during the COVID-19 pandemic

Filipe Carvalho 1 · Ailín C. Rogers 1 · Tou-Pin Chang 1 · Yinshan Chee 1 · Dhivya Subramaniam 1 · Gianluca Pellino 2,3 · Katy Hardy 1 · Christos Kontovounisios 1,4,5 · Paris Tekkis 1,4,5 · Shahnawaz Rasheed 1 · London Colorectal Cancer Hub Network Collaborators

Received: 31 August 2021 / Accepted: 13 December 2021 / Published online: 3 March 2022 © The Author(s) 2022

Abstract
The outbreak of the COVID-19 pandemic produced unprecedented challenges, at a global level, in the provision of cancer care. With the ongoing need in the delivery of life-saving cancer treatment, the surgical management of patients with colorectal cancer required prompt significant transformation. The aim of this retrospective study is to report the outcome of a bespoke regional Cancer Hub model in the delivery of elective and essential colorectal cancer surgery, at the height of the first wave of the COVID-19 pandemic. 168 patients underwent colorectal cancer surgery from April 1st to June 30th of 2020. Approximately 75% of patients operated upon underwent colonic resection, of which 47% were left-sided, 34% right-sided and 12% beyond total mesorectal excision surgeries. Around 79% of all resectional surgeries were performed via laparotomy, and the remainder 21%, robotically or laparoscopically. Thirty-day complication rate, for Clavien–Dindo IIIA and above, was 4.2%, and 30-day mortality rate was 0.6%. Re-admission rate, within 30 days post-discharge, was 1.8%, however, no patient developed COVID-19 specific complications post-operatively and up to 28 days post-discharge. The established Cancer Hub offered elective surgical care for patients with colorectal cancer in a centralised, timely and efficient manner, with acceptable post-operative outcomes and no increased risk of contracting COVID-19 during their inpatient stay. We offer a practical model of care that can be used when elective surgery “hubs” for streamlined delivery of elective care needs to be established in an expeditious fashion, either due to the COVID-19 pandemic or any other future pandemics.

Keywords COVID-19 · Colorectal surgery · Cancer · SARS-CoV-2

The list of London Colorectal Cancer Hub Network Collaborators members were listed in Acknowledgements section.

Christos Kontovounisios
c.kontovounisios@imperial.ac.uk
Filipe Carvalho
Filipe.carvalho@rmh.nhs.uk
Ailín C. Rogers
Ailinrogers@gmail.com
Tou-Pin Chang
t.chang@nhs.net
Yinshan Chee
ychee01@qub.ac.uk
Dhivya Subramaniam
dsubramaniam@nhs.net
Gianluca Pellino
gipe1984@gmail.com
Katy Hardy
Katy.Hardy@rmh.nhs.uk

Paris Tekkis
p.tekkis@imperial.ac.uk
Shahnawaz Rasheed
Shahnawaz.Rasheed@rmh.nhs.uk

1 Department of Colorectal Surgery, The Royal Marsden Hospital NHS Foundation Trust, London SW3 6JJ, UK
2 Department of Advanced Medical and Surgical Sciences, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy
3 Colorectal Surgery, Vall d’Hebron University Hospital, Barcelona, Spain
4 Chelsea and Westminster Hospitals NHS Foundation Trust, London SW10 9NH, UK
5 Department of Surgery and Cancer, Imperial College London, London SW10 9NH, UK
Introduction

SARS-CoV-2 (responsible for COVID-19) was declared a pandemic by the World Health Organization (WHO) in early 2020, and a 3-month nationwide lockdown was implemented in the United Kingdom (UK) on March 23rd in an attempt to reduce virus transmission [1, 2]. With the initial surge of COVID-19 cases, healthcare staff were redeployed outside of usual roles to care exclusively for infected patients, while other staff members were affected or forced to self-isolate due to disease exposure. Hospitals were faced with the downstream challenges of increased numbers of acutely unwell patients in combination with limited bed capacity and critical staff and resource shortages [3, 4]. In recognition of the broader effects of COVID-19 on healthcare delivery, the UK National Health Service (NHS) sought to rationalise resources to create bed capacity and facilitate care for those with COVID-19, focussing on limiting spread of the disease and minimising fatalities. As part of this strategy, elective surgical procedures were suspended on April 15th for three months nationwide [5, 6].

The deferral of elective surgery was not the only factor impacting cancer care in the pandemic. Intensive care units (ICU) were filled with COVID-19 patients, with a resultant lack of post-operative ICU beds for patients requiring emergency surgery [7]. Staff shortages and social distancing measures led to a dramatic reduction in patient access to in-person outpatient appointments and diagnostics. Fear of contracting nosocomial COVID-19 infection led to underreporting of symptoms by patients and hesitancy to present for medical treatment when indicated [7]. COVID-19 exposure in the peri-operative setting is associated with poor post-operative outcomes and rendered surgeons and patients alike reticent to undertake major surgery in the setting of the pandemic [8]. The cumulative effect of these factors contributed to significant disruptions in cancer care and services nationally [9].

The pandemic represented a rapidly evolving scenario, with unprecedented challenges to the healthcare systems globally, and several countermeasures were suggested to provide care to patients with colorectal conditions [9–11]. To ensure continuity of colorectal cancer services during the COVID-19 pandemic, the Royal Marsden Partners Cancer Hub (RM Partners Cancer Hub) was established. This Cancer Hub was collaboratively designed with the sole aim of centralising resources for patients with colorectal and anal cancer across the London region, ensuring optimal delivery of cancer care whilst minimising patient exposure to COVID-19.

The aim of this study is to investigate the feasibility and usability of this bespoke Cancer Hub model in delivering elective colorectal and anal cancer surgery services as a regional collaborative network at the height of the first wave of the COVID-19 pandemic, whilst detailing the steps that led to its inception.

Materials and methods

This is a retrospective study aimed to describe the strategies adopted at several UK centres to ensure continued care to colorectal cancer patients during the pandemic, and to report on the outcome of the network. The study was conducted following the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) Statement [12].

Royal Marsden partners cancer hub creation

A collaborative network was devised to provide a centralised surgical pathway for patients with colorectal or anal cancer across the London region during the COVID-19 pandemic. This initiative was created for patients within the catchment area who required time-critical cancer surgery but for whom access to treatment in their local trust was affected by the COVID-19 surge.

Colorectal surgeons specialising in cancer treatment from all NHS trusts in the greater north to south west London area were invited to join at inception. Eligible patients were discussed centrally at a weekly multidisciplinary team meeting (MDT) and categorised by consensus agreement of a quorum of surgeons, with surgical treatment performed at either of two designated ‘COVID-19 free’ surgical sites in London, facilitating other hospitals in the network to focus on pandemic care.

The Royal Marsden Hospital (RMH) and BUPA Cromwell Hospital (BCH) were chosen as the ‘COVID-19 free’ sites for delivery of surgical care for several reasons. Both hospitals are located in central/west London, facilitating ease of access for patients and surgeons alike. All patients admitted to or attending either site could be forecasted in advance, allowing self-isolation, screening and testing for COVID-19 prior to any attendance. All of these factors collaboratively ensured that both hospitals could function independently from other NHS units in the area to deliver elective cancer care in a way that was safe for patients, while ensuring ongoing care to acutely unwell COVID-19 patients elsewhere, and thus the RM Partners Cancer Hub was created (Fig. 1).

Patient selection

Patients were included if they had colorectal or anal cancer and were deemed suitable for surgery following completion of diagnostics and MDT discussion at their respective NHS
Trusts. Patients were excluded for referral if they had active COVID-19 infection. Referral to the RM Partners Cancer Hub was done using a standardised online referral form. The referring NHS Trusts were responsible for communicating to the patient their decision to offer surgery through the RM Partners Cancer Hub and advising the patients and their respective households to commence self-isolation immediately (Fig. 2).

Patient prioritisation

Strategic prioritisation of cases for diagnosis and management was employed to mitigate complications attributable to delays. All RM Partners Cancer Hub referrals were listed for discussion within seven days from the date of referral at a centralised Clinical Prioritisation Group (CPG) online meeting. Weekly CPG meetings were chaired by a CPG lead and virtually attended by consultant surgeons or senior clinical representatives from each participating NHS Trust.

Clinical prioritisation was made in accordance with NHS England published guidelines for the management of cancer patients during the COVID-19 pandemic [13], with patients categorised into three priority levels:

- **Priority level 1a and 1b patients** were those requiring life-saving surgery within 24 or 72 h, respectively. These included patients with clinical presentation of obstruction, perforation or haemorrhage from colorectal or anal cancer.
- **Priority level 2 patients** were defined as those who needed elective surgery with the expectation of cure within 4 weeks. These included colorectal or anal cancer patients who were at risk of imminent obstruction that were not suitable for stenting; stage 1 to 3 colorectal cancer patients who did not meet requirements for neoadjuvant treatment; and those colorectal or anal cancer patients’ post-chemotherapy and/or radiotherapy who required curative surgery.
- **Priority level 3 patients** were defined as those who required elective surgery that could be performed within 10 to 12 weeks with no predicted negative oncological outcome.

Theatre allocation

CPG-prioritised cases were allocated theatre slots in a transparent, mutual and cohesive manner, with agreement between NHS Trust representatives and a CPG meeting quorum of at least four consultant surgeons. The forum was in the form of a virtual video conference meeting to facilitate real-time screen-sharing of theatre calendars for both surgical sites. Cases were consecutively scheduled into available theatre slots on the basis of patient priority and availability of the primary surgeons.

High risk anaesthetic cases or complex surgeries that required the input of multi-visceral surgical teams were performed in RMH, the designated high-risk surgical site provider. The referring NHS Trusts were responsible for communicating the outcome of the CPG meeting to the patient including the date of surgery or its rejection, and for advising the patient and their household to continue self-isolation for at least 7 days prior to their surgery (Fig. 2).

Pre-operative assessment

The pre-operative assessments of CPG-prioritised cases were undertaken by the RM Partners Cancer Hub including the first stage of informed consent indicating the COVID-19 risks. The referring NHS Trusts were requested in advance to provide all the relevant pre-operative clinical information and investigations. At times during the pandemic, national and international guidelines changed for pre-operative isolation and investigation requirements for elective surgery, and the CPG had a dynamic approach to implementing and adjusting guidelines accordingly. All patients were required to have self-isolated for at least 7 days, at certain points, 14 days prior to surgery; have a negative COVID swab 48 h prior to surgery, as well as a non-contrast CT chest confirming no COVID changes when patient likely to require post-operative ICU admission.
Fig. 2  Cancer hub pathway
Clinical oversight and governance

The clinical team onsite at the RMH provided clinical oversight of all patients, however those admitted for surgery remained under the direct care of their consultants from the referring NHS Trusts, who ensured their own teams reviewed the patients daily. Clinician indemnity was covered by an NHS England agreement. All major colorectal and anal cancer resections were operated on by at least two consultant surgeons from their referring NHS Trusts donned with full personal protective equipment (PPE) and with adherence to positive flow ventilation protocol as per local guidelines. Open surgery was employed preferentially in the early stages due to concerns about virus aerosolization. Subsequently, an AirSeal® System was used to minimise aerosol contamination during laparoscopic procedures. All patients were anaesthetised by consultant anaesthetists and all resectional surgeries were admitted to critical care post-operatively. All patients in the post-operative period were reviewed daily by a consultant surgeon with the support of senior registrars and an advanced nurse practitioner, in addition to resident medical officers at both surgical site providers, with access to a designated consultant surgeon on-call for out-of-hours emergencies.

Patient demographics, clinicopathological characteristics and post-operative outcomes were recorded in a prospectively maintained database including electronic and medical records, endoscopic, radiological, histopathology reports and discharge summaries. A clinical governance team was established within the RM Partners Cancer Hub with weekly review of audit data and theatre activity including cancellations and post-operative complications. All consultants from involved NHS Trusts were invited to join in the RM Partners Cancer Hub surgical audit monthly online meetings where all surgical cases, complications, 30-day return to theatres and 30-day re-admissions were discussed. All patients received a 28-day post-discharge telephone-based welfare check, from the RM Partners Cancer Hub, where readmission, return to theatre and absence or not of COVID-19 symptoms, was ascertained.

All aspects of inception and implementation of the RM Partners Cancer Hub, including data collection and dissemination was approved by the Institutional Review Board of RMH.

Data of interest

This study assessed the performance of the established Hub and the impact on theatres utilisation. The outcome of patients treated within the network was collected. Baseline patient characteristics, tumour-related information, and perioperative events were obtained from a prospectively maintained database. Thirty-day complications were graded according to the Clavien–Dindo classification.

Statistical analysis

Categorical data are reported as absolute values (percentages), whereas continues data are presented as mean ± standard deviation (SD).

Results

The RM Partners Cancer Hub was established on April 1st 2020. Seven NHS Trusts across north to south west London participated (Fig. 1). This comprised of 7 NHS Trusts which deliver care for a population of over 5 million people.

Cancer hub performance

176 patients were referred through the online referral form for discussion at the CPG meeting during the peak of the first wave of COVID-19. This period lasted from April 1st to June 30th. The mean time from referral to CPG discussion was 5.7 ± 0.7 days, from referral to anaesthetic assessment was 9.0 ± 1.3 days, and from referral to surgery (all priorities) was 16.3 ± 1.8 days. Of those 176 patients discussed through the CPG meeting, eight patients did not subsequently undergo surgery at RM Partners Cancer Hub during the aforementioned time period. 4 patients were deemed not fit from an anaesthetic point of view; two patients had disease progression at the time of CPG discussion or restaging just prior to surgery, and following MDT discussion, referred back to their referral centre for alternative treatment; one patient opted not to undergo surgery and one patient pre-operative CT chest showed indeterminate features for COVID and therefore surgery was delayed and ultimately underwent surgery in their referral centre after the Cancer Hub dissolution.

Theatre utilisation

Ultimately 168 patients underwent colorectal or anal cancer surgery at the RM Partners Cancer Hub during the study period; 12 patients were categorised as priority 1b, 142 patients were priority 2 and the remaining 14 were priority 3. 88 patients were operated on in the RMH, and the remainder 80 in the BCH. Thirty-five consultant surgeons participated in the surgeries, with the patient’s primary consultant leading their operation in all cases (Table 1).

Approximately five percent of cases were cancelled within 48 h prior to surgery, and performed at a later stage, meaning that ninety-five percent of the 239 available theatre sessions (each session comprised of a four-hour operating
Operative outcomes

Patient and tumour characteristics with post-operative outcomes are shown on Table 2. Around three quarters of patients operated upon underwent colonic resection, of which 47% were left-sided resections, 34% right-sided resections and 12% beyond total mesorectal excision (TME) surgeries. Around 79% of all resectional surgeries were performed via laparotomy, while the remainder 21% were performed either robotic or laparoscopically.

Seven patients (4.2%) developed Clavien–Dindo IIIA and above complications. Of these, four patients required radiological-guided drainage of post-operative collection and one required coronary stenting following post-operative myocardial infarction. One patient developed anastomotic leak 13 days after an open right hemicolecotomy and returned to theatre for washout and stoma formation. One patient died from ischaemic bowel following myocardial infarction approximately three days following an open anterior resection (30-day mortality rate of 0.6%). None of the patients developed COVID-19 specific complications post-operatively and up to 28 days post-discharge.

Three patients (1.8%) required re-admission to their local hospital, within 30 days post-discharge. 1 patient suffered from urosepsis, 1 patient from bloodstream sepsicaemia and 1 other from nausea and vomiting. In all 3 cases, patients were managed with pharmacological treatment.

Discussion

The SARS-CoV-2 pandemic deeply affected surgical practice globally, with a reduction of emergency admissions and surgical procedures—for several reasons, including staff shortages, healthcare workers fear of infections [3, 7, 14–18]—eventually impacting patients suffering from colorectal cancer. [2, 19, 20]

Evidence supports the feasibility and safety of surgery for common colorectal conditions that, even if non-emergent, might impair patient’s quality of life and long-term survival if treatment is delayed [21–23]. However, it is important that strategies are developed to mitigate the risk of complications related to perioperative SARS-CoV-2 infection [11, 15, 20–22, 24–29]—which is reported to have a detrimental effect on short-term outcomes of surgery [30].

With the arrival of the subsequent waves of COVID-19, and with an unforeseen future of possible lockdowns, the RM Partners Cancer Hub offers an opportunity to model similar cancer or elective surgery “hubs” for streamlined delivery of elective care in COVID-free settings. Risk modelling predicts that a 3-month delay to elective surgery for all cancers could cause almost 5000 deaths per year in England alone and supersedes the risk of COVID-19 even in an age-adjusted population, in terms of life-years lost9. Delays to diagnostics and endoscopic or surgical treatments result in a higher burden of advanced and aggressive tumours, as well as in those who present with obstruction or perforation, with downstream negative effects on survival rate and oncologic outcomes [31]. Thus, there is undoubtedly a rationale for ensuring continuity of cancer care at the current and future times.

The RM Partners Cancer Hub was created as an innovative attempt by the colorectal surgery network in west London to deliver cancer care in the midst of the COVID-19 pandemic. The details herein illustrate the steps taken to ensure a robust centralisation process, upholding high standards of clinical governance, whilst retaining individual surgeon autonomy over the care of their own patients, albeit outside of their usual geographical sites of employment. Despite significant logistic and operational challenges, the immediacy of the pandemic allowed quick troubleshooting, ensuring delivery of cancer care in an appropriate, safe and efficient way in one of the biggest worldwide healthcare crisis of this century.

Of note is that for the category 1b, which refers to patients requiring life-saving surgery within 72 h; the median time from RM Cancer Hub referral to surgery was 7.3 ± 1.2 days.

Table 1 Surgical case volume from London NHS Trusts participating in the RM Partners Cancer Hub

| NHS trust                                      | Number | Percentage |
|------------------------------------------------|--------|------------|
| Chelsea and Westminster Hospital              | 45     | 27%        |
| Royal Marsden Hospital                        | 31     | 18%        |
| London North West University Health-care NHS Trust / St Mark’s Hospital | 26     | 15%        |
| Hillingdon Hospital                           | 23     | 14%        |
| Croydon University hospital                   | 21     | 12%        |
| Epsom and St Helier Hospital                  | 15     | 9%         |
| St George’s Hospital                          | 7      | 4%         |

...
### Table 2  Patient characteristics, time to surgery, operative details and outcomes from surgeries performed by seven participating NHS Trusts at RM Partners Cancer Hub (values given as mean ± SD)

| Baseline characteristics ($n=168$) |  |
|-----------------------------------|--|
| Age > 65                          | 82 (48.8%) |
| Men                               | 73 (43.5%) |
| Body mass index (BMI) > 30        | 105 (62.5%) |
| Smoker                            | 73 (43.4%) |
| The American Society of Anaesthesiologists (ASA) Physical Status Classification  |
| 1                                 | 13 (7.7%) |
| 2                                 | 83 (49.4%) |
| 3                                 | 70 (41.7%) |
| 4                                 | 2 (1.2%) |
| Time (days) from Royal Marsden Cancer Hub referral to surgery  |
| Overall                           | 16.3 ± 1.8 |
| Category 1a                       | N/a |
| Category 1b                       | 7.3 ± 1.2 |
| Category 2                        | 17.0 ± 12.3 |
| Category 3                        | 13.6 ± 11.0 |
| Tumour site                       |  |
| Right colon                       | 37 (22%) |
| Transverse colon                  | 10 (5.9%) |
| Left colon                        | 41 (24.4%) |
| Rectum                            | 53 (31.5%) |
| Anus                              | 16 (9.5%) |
| Other                             | 11 (6.5%) |
| Case mix and type                 | 125 (74.4%) |
| Resectional                       |  |
| Right colonic                     | 42 |
| Left colonic/anterior             | 59 |
| Right and left sided              | 6 |
| Beyond Total Mesorectal Excision (TME) | 15 |
| Small bowel/ovary                 | 3 |
| Non-resectional                   |  |
| Examination Under Anaesthetic (EUA) with biopsies ± | 43 (25.6%) |
| Colonoscopy or Flexi-Sigmoidoscopy | 18 |
| Excision of lesion ± endoscopically | 5 |
| Defunctioning stoma               | 5 |
| Stoma reversal                    | 5 |
| Diagnostic laparoscopy            | 2 |
| Stoma refashioning                | 1 |
| Transanal Minimally Invasive Surgery (TAMIS) | 6 |
| Excision of abdominal wall mass   | 1 |
| Surgical approach for resectional surgery ($n=125$)  |
| Open                              | 99 (79.2%) |
| Laparoscopic                      | 22 (17.6%) |
| Robotic                           | 4 (3.2%) |
| Surgical outcome for resectional surgery ($n=125$)  |
| Anastomosis, without stoma        | 73 (58.4%) |
| Anastomosis, with stoma           | 22 (17.6%) |
| Stoma with no anastomosis         | 30 (24%) |
| Length of stay (days)             |  |
| Overall                           | 7.1 ± 1.0 |
| Open                              | 9.3 ± 5.9 |
| Laparoscopic / Robotic            | 7.0 ± 4.7 |
This clearly falls outside the NHS recommended time frame. The reason behind it was that some of the category 1b patients were only discussed formally in the CPG after they had their surgery, as CPG meetings were held once weekly, and some cases couldn’t wait until the meeting occurred. In these specific cases, informal discussions between senior members of the CPG Clinical Lead and respective Consultants took place in advance and a joint decision was made to proceed with surgery without further delay.

The logistic challenges that were encountered during the inception of the Cancer Hub were overcome with creative thinking, dynamism and the support of NHS stakeholders, patients and clinicians alike. The majority of patients had open surgery; this reflects the case mix of advanced cancers that are treated within the network, but more accurately reflects the concerns raised about aerosolising procedures at the time. [16, 17, 32–35]. However, the safety of minimally invasive surgery during the pandemic is now accepted [10, 32, 36]. Robotic surgery was almost entirely side-lined to facilitate swifter operations. Digital and virtual means of communication were indispensable in the functioning of the network. Teams and patients quickly got used to new video-conferencing and online referral pathways, and this actually improved levels of participation as well as documentation for audit, whilst allowing the social distancing required to prevent virus transmission. Participation from each trust was important, so that stakeholders, especially clinicians, felt equally accountable and represented at each step of the process. A key and fundamental feature of the model was equity in the theatre allocation process, so that each patient was allocated a surgical slot on a real-time theatre calendar based on need by consensus, and their surgeons were facilitated to travel to the designated surgical sites around their other workplace commitments. The fairness and transparency in this process ensured a positive effect on the whole network’s commitment to the RM Partners Cancer Hub and is reflected in the fact that 35 surgeons performed 168 surgeries over a 13-week time period, without any delays to patient care.

Despite the overwhelming drawbacks of the COVID-19 pandemic, a few positive changes arose. The eagerness to embrace telemedicine is undoubtedly one of the greater achievements in healthcare over the last year and may improve patient input, decrease non-attendances and generate cost savings within the system, as well as national economic savings due to reduced patient absenteeism. Telemedicine also allows those living remotely or with mobility difficulties increased options for accessing care [2, 11, 37]. It must also be highlighted that one of the most important achievements of this collaboration was that no patient developed a nosocomial COVID-19 infection post-operatively, at a point in the pandemic when up to 15% of inpatient COVID-19 infections were hospital-acquired [38]. During the time-period of the hub, there was a small percentage of inpatients, at either of the two hospital sites, COVID-19 positive. This demonstrates that centralising cancer care to elective-only or designated COVID-free sites can reduce COVID-19 risk to patients who are already vulnerable by virtue of their cancer diagnosis.

**Conclusion**

The RM Partners Cancer Hub offered elective surgical care for patients with colorectal and anal cancer in a centralised, timely and efficient manner, with acceptable post-operative outcomes and no increased risk of contracting COVID-19 during their inpatient visit. This model may be used in future for when centralising care needs to be implemented in an expeditious fashion.

**Acknowledgements** London Colorectal Cancer Hub Network Collaborators: A. Karim, A. Chung, A. Ramwell, R. Hagger, N. West, L. Toquero, A. Gupta, P. Toomey, A. Raja, N. Pawa, S. Mills, O. Warren, C. Nicolay, B. Thava, N. Daulatzai, I. Jenkins, D. Miskovic, E. Burns, A. Antoniou, T. Agarwal, N. Sinha, A. Slessor, A. Prabhudesai, Y. Mohsen A. Myers, S. Harris, S. Mohamed, M. Abulafi, A. Shanmuganandan, J. Van Dellen.

**Declarations**

**Conflict of interest** The authors declare that they have no conflicts of interest and that this study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors affirm that this manuscript is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

**Ethical approval** All procedures performed in studies involving human participants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Informed consent** Informed consent was obtained from all individual participants included in the study.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. UK Government (2020) Prime Minister's statement on coronavirus (COVID-19): 23 March 2020. https://www.gov.uk/government/speeches/pm-address-to-the-nation-on-coronavirus-23-march-2020. Accessed 26 December 2020
2. Spinelli A, Pellino G (2020) COVID-19 pandemic: perspectives on an unfolding crisis. Br J Surg 107(7):785–787. https://doi.org/10.1002/bjs.11627
3. COVIDSurg Collaborative (2021) COVID-19-related absence among surgeons: development of an international surgical workforce prediction model. BJS Open 5(2):21. https://doi.org/10.1093/bjsoopen/zraa021
4. Tan YQ, Wang Z, Yap QV, Chan YH, Ho RC, Hamid ARAH, Landaluze-Olavarria A, Pellino G, Gauhar V, Chand M, Wroclawski ML, Hamed BMZ, Ling SK, Sengupta S, Gallo G, Chiu PK, Tanidir Y, Tallada MPV, Garcia BN, Colleoni R, Abidin ZAZ, Campi R, Esperto F, Carrion D, Eltermann D, Chang ASJ, Ng ACF, Moschini M, Rivas JG, Mayol J, Teoh JY, Chiong E (2021) Psychological health of surgeons in a time of COVID-19: a global survey. Ann Surg. https://doi.org/10.1097/SLA.0000000000004775
5. NHS England and NHS Improvement (2020) Next Steps on NHS Response to COVID-19: Letter from Sir Simon Stevens and Amanda Pritchard. https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/20200317-NHS-COVID-letter-FINAL.pdf. Accessed 26 December 2020
6. Iacobucci G (2020) COVID-19: all non-urgent elective surgery is suspended for at least three months in England. BMJ 368:m1106. https://doi.org/10.1136/bmj.m1106
7. Reichert M, Sartelli M, Weiand MA, Doppstadt C, Hecker M, Reinisch-Liese A, Bender F, Asokveda I, Padberg W, Coccolini F, Catena F, Hecker A, WSES COVID-19 emergency surgery survey collaboration group (2020) Impact of the SARS-CoV-2 pandemic on emergency surgery services-a multi-national survey among WSES members. World J Emerg Surg 15(1):64. https://doi.org/10.1186/s13017-020-00341-0
8. Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, Zhan LY, Jia Y, Zhang L, Liu D, Xia ZY, Xia Z (2020) Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine 21:100331. https://doi.org/10.1016/j.eclinm.2020.100331
9. Torzilli G, Viganò L, Galvanin J, Castoro C, Quagliuolo V, Spinelli A, Zerbi A, Donadon M, Montorsi M, COVID-SURGE-ITA Group (2020) A snapshot of elective oncological surgery in Italy during COVID-19 emergency: pearls, pitfalls, and perspectives. Ann Surg 272(2):e112–e117. https://doi.org/10.1097/SLA.0000000000004081
10. Di Saverio S, Pata F, Gallo G, Carrano F, Scorzà A, Sileri P, Smart N, Spinelli A, Pellino G (2020) Coronavirus pandemic and colorectal surgery: practical advice based on the Italian experience. Colorectal Dis 22(6):625–634. https://doi.org/10.1111/codi.15056
11. Pellino G, Vaizey CJ, Maeda Y (2020) European Society of Coloproctology (ESCP) Guideline Committee The COVID-19 pandemic: considerations for resuming normal colorectal services. Colorectal Dis 22(9):1006–1014. https://doi.org/10.1111/codi.15313
12. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenburgroucke JP (2008) The strengthening of the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344–349. https://doi.org/10.1016/j.jclinepi.2007.11.008
13. Royal College of Surgeons (2020) Clinical guide to surgical prioritisation during the coronavirus pandemic. https://www.rcseng.ac.uk/coronavirus/surgical-prioritisation-guidance. Accessed 26 December 2020
14. An Y, Bellato V, Konishi T, Pellino G, Sensi B, Siragusa L, Francheschilli M, Sica GS; S-COVID Collaborative Group (2020) Surgeons’ fear of getting infected by COVID19: A global survey. Br J Surg 107(11):e543–e544. https://doi.org/10.1002/bjs.11835
15. COVIDSurg Collaborative (2020) Delaying surgery for patients with a previous SARS-CoV-2 infection. Br J Surg 107(12):e601–e602. https://doi.org/10.1002/bjs.12050
16. Bracale U, Podda M, Castiglioni S, Peltrini R, Sartori A, Arezzo A, Coricione F, Agresta F; CLOUD-19 Collaborative Group (2021) Changes in surgical behaviours during the COVID-19 pandemic. The SICSE CLOUD19 Study. Updates Surg 73(2):731–744. https://doi.org/10.1007/s15304-021-01010-w
17. Ielpo B, Podda M, Pellino G, Pata F, Caruso R, Gravante G, Di Saverio S; ACIE Appy Study Collaborative (2021) Global attitudes in the management of acute appendicitis during COVID-19 pandemic: ACIE Appy Study. Br J Surg 108(6):717–726. https://doi.org/10.1002/bjs.11999
18. Javannard-Emamghissi H, Boyd-Carson H, Hollyman M, Doleman B, Adiamah A, Lund JN, Clifford R, Dickerson L, Richards S, Pearce L, Cornish J, Hare S, Lockwood S, Mouy SJ, Tierney GM; COVID: HAREM (Had Appendicitis, Resolved/Recurred Emergency Morbidity/Mortality) Collaborators Group (2020) The management of adult appendicitis during the COVID-19 pandemic: an interim analysis of a UK cohort study. Tech Coloproctol 25(4):401–411. https://doi.org/10.1007/s10151-020-02297-4
19. PelvEx Collaborative (2020) The impact of the COVID-19 pandemic on the management of Locally Advanced Primary/Recurrent Rectal Cancer. Br J Surg 107(11):e547–e548. https://doi.org/10.1002/bjs.11893
20. COVIDSurg Collaborative (2020) Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans. Br J Surg 107(11):1440–1449. https://doi.org/10.1002/bjs.11746
21. Glasbej JC, Nepogodiev D, Simoes JFF, Omar O, Li E, Venn ML, Pgdme AC, MK, Caprizi V, Chaudhry D, Desai A, Edwards JG, Evans JP, Fiore M, Videria JF, Ford SJ, Ganly I, Griffiths EA, Gujuri RR, Kolias AG, Kaafarani HMA, Minaya-Bravo A, McKay SC, Mohan HM, Roberts KJ, San Miguel-Méndez C, Pockney P, Shaw R, Smart NJ, Stewart GD, SundarMrCqg S, Vidy R, Bhangu AA (2020) Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic:
an international, multicenter. Comparative Cohort Study. J Clin Oncol 39(1):66–78. https://doi.org/10.1200/JCO.20.01933

22. COVIDSurg Collaborative (2020) Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic. Colorectal Dis. https://doi.org/10.1111/codi.15431

23. Rottoli M, Pellino G, Tanzanu M, Baldi C, Frontali A, Carvello M, Foppa C, Kontovounisios C, Tekkis P, Colombo F, Sancho-Muriel J, Frasson M, Danelli P, Celentano V, Spinelli A, Panis Y, Sampietro GM, Poggio G (2021) Inflammatory bowel disease patients requiring surgery can be treated in referral centres regardless of the COVID-19 status of the hospital: results of a multicentric European study during the first COVID-19 outbreak (COVIDSurg). Updates Surg. https://doi.org/10.1007/s13304-021-01119-y

24. Lui RN, Wong SH, Sánchez-Luna SA, Pellino G, Bollopi S, Wong MY, Chiu PWY, Sung JJY (2020) Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol 35(5):749–759. https://doi.org/10.1111/jgh.15053

25. Bellato V, Konishi T, Pellino G, An Y, Piciocchi A, Sensi B, Vilallonga R, Pellino G, Almirante B, Domínguez González JM, Leventoğlu S, Menteş B, Şenol E, Zimmerman D, Pellino G, Pelto GM, Poggioli G (2021) Inflammatory bowel disease patients requiring surgery can be treated in referral centres regardless of the COVID-19 status of the hospital: results of a multicentric European study during the first COVID-19 outbreak (COVIDSurg). Updates Surg. https://doi.org/10.1007/s13304-021-01126-z

26. COVIDSurg Collaborative; GlobalSurg Collaborative, (2021) COVID-19 in global surgical practices. J Glob Health 10(2):020507. https://doi.org/10.7189/jogh.10.020507

27. Huddy JR, Rasheed S, Tilney HS (2020) Continuation of minimally invasive surgery in the COVID-19 pandemic. Tech Coloproctol 24(10):1105–1106. https://doi.org/10.1007/s10151-020-02333-3

28. COVIDSurg Collaborative (2020) Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic. Colorectal Dis. https://doi.org/10.1111/codi.15431

29. COVIDSurg Collaborative (2020) Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: an international prospective cohort study. Anaesthesia 76(6):748–758. https://doi.org/10.10111/anae.15458

30. COVIDSurg Collaborative (2020) Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet 396(10243):27–38. https://doi.org/10.1016/S0140-6736(20)31182-X

31. Sud A, Jones ME, Broggio J, Loveday C, Torr B, Garrett A, Nicol DL, Jhanji S, Boyce SA, Gronthoud F, Ward P, Handy JM, Yousaf N, Larkin J, Suh YE, Scott S, Pharao PDP, Swanton C, Abbosh C, Williams M, Lyrazeitopoulos G, Houlston R, Turnbull C (2020) Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol 31(8):1065–1074. https://doi.org/10.1093/annonc/mdz310

32. COVIDSurg Collaborative (2020) Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic. Colorectal Dis. https://doi.org/10.1111/codi.15431

33. COVIDSurg Collaborative (2020) Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic. Colorectal Dis. https://doi.org/10.1111/codi.15431

34. COVIDSurg Collaborative (2020) Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic. Colorectal Dis. https://doi.org/10.1111/codi.15431

35. Prieto M, Ielpo B, Jiménez Fuertes M, González Sánchez MDC, Blanco-Colino R, Petrola C, Armengol M (2021) A risk-based screening approach to patients needing surgery during the de-escalation phase of COVID-19 pandemic. Surg Innov 28(2):239–244. https://doi.org/10.11177/1553350620975886

36. COVIDSurg Collaborative; GlobalSurg Collaborative, (2021) COVID-19 in global surgical practices. J Glob Health 10(2):020507. https://doi.org/10.7189/jogh.10.020507

37. COVIDSurg Collaborative; GlobalSurg Collaborative, (2021) COVID-19 in global surgical practices. J Glob Health 10(2):020507. https://doi.org/10.7189/jogh.10.020507

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.